Delving into the Latest Updates on 23-valent pneumococcal polysaccharide vaccine(Chengdu Institute of Biological Products) with Synapse

Overview

Basic Info

Drug Type

Inactivated vaccine, Prophylactic vaccine, Multivalent vaccine

Synonyms

23-Valent Pneumococcal Polysaccharide Vaccine, 23价肺炎球菌多糖疫苗（成都生物制品研究所）, 惠益康

Target-

Mechanism

Immunostimulants

Therapeutic Areas

Infectious DiseasesRespiratory Diseases

Active Indication

Pneumonia, Bacterial

Inactive Indication-

Originator Organization

Chengdu Institute of Biological Products

Active Organization

Chengdu Institute of Biological Products

Inactive Organization-

Drug Highest PhaseApproved

First Approval Date

CN (24 Apr 2006),

Pneumonia, Bacterial

Regulation-

Login to view timeline

This study is an open-label,single center phase Ⅳ clinical trial of combined immunization with quadrivalent influenza vaccine and 23-valent pneumococcal polysaccharide vaccine.The purpose of this study is to evaluate the safety and immunogenicity of combined immunization with quadrivalent influenza vaccine and 23-valent pneumococcal polysaccharide vaccine in the elderly aged 60 years and above.

Start Date13 Nov 2021

Sponsor / Collaborator

Sinovac Biotech Co. Ltd.

NCT05079152

/ Unknown statusPhase 4

A Randomized, Controlled, Multicenter Phase 4 Clinic Trial to Evaluate the Immunogenicity and Safety of Combined Immunization of Inactivated SARS-CoV-2 Vaccines (Vero Cell) (COVAX) (Produced in Wuhan) and 23-valent Pneumococcal Polysaccharide Vaccine (PPV23) or Quadrivalent Inactivated Influenza Vaccine (IIV4)

Subjects will be recruited and divided into 3 groups:
Experimental Group (468 subjects): 1st dose : combined vaccination of COVAX+PPV23, 2nd dose: combined vaccination of COVAX+IIV4; Control Group A (468 subjects): 1st dose: COVAX only, 2nd dose: COVAX only; Control Group B (468 subjects): 1st dose: PPV23 only, 2nd dose: IIV4 only.
Blood samples will be collected 3 times:
before the 1st dose of vaccinatioin; before the 2nd dose of vaccination; 28 days after the 2nd dose of vaccination.
The immunogenicity and safety of both experimental and control groups will be analyzed.

Start Date06 May 2021

Sponsor / Collaborator

China National Biotec Group Co., Ltd.

[+5]

ChiCTR2100054674

/ RecruitingPhase 4IIT

A randomized, controlled, multi-center clinical study to evaluate the immunogenicity and safety of the new coronavirus inactivated vaccine and the 23-valent pneumococcal polysaccharide vaccine and the quadrivalent influenza virus split vaccine at the same time

Start Date06 May 2021

Sponsor / Collaborator-

100 Clinical Results associated with 23-valent pneumococcal polysaccharide vaccine(Chengdu Institute of Biological Products)

Login to view more data

100 Translational Medicine associated with 23-valent pneumococcal polysaccharide vaccine(Chengdu Institute of Biological Products)

Login to view more data

100 Patents (Medical) associated with 23-valent pneumococcal polysaccharide vaccine(Chengdu Institute of Biological Products)

Login to view more data

2

Literatures (Medical) associated with 23-valent pneumococcal polysaccharide vaccine(Chengdu Institute of Biological Products)

01 Jan 2024·Vaccine

Immune thrombocytopenic purpura and Guillain-Barré syndrome after 23-valent pneumococcal polysaccharide vaccination in Japan: The vaccine effectiveness, networking, and universal safety (VENUS) study

Article

Author: Sato, Shuntaro ; Murata, Fumiko ; Katsuta, Tomohiro ; Fukuda, Haruhisa ; Kawazoe, Yurika ; Maeda, Megumi ; Kamidani, Satoshi ; Takahashi, Masaki

BACKGROUNDTo address the lack of an active vaccine safety surveillance system in Japan, the Vaccine Effectiveness, Networking, and Universal Safety (VENUS) study was initiated in 2021 as a pilot system using existing health insurance claims data and vaccination records.METHODSThis study evaluated the value of the VENUS study by assessing the incidence of immune thrombocytopenic purpura (ITP) and Guillain-Barré syndrome (GBS) following vaccination with the 23-valent pneumococcal polysaccharide vaccine (PPSV23) using a self-controlled case series (SCCS) design.RESULTSIncidence rate ratios for ITP during 28-day and 42-day risk periods were 0.89 (95% confidence interval [CI], 0.12-6.4), and 0.58 (95% CI, 0.081-4.2), respectively. Neither was statistically significant. Incidence rate ratios could not be estimated for GBS due to the limited sample size.CONCLUSIONThe VENUS study can provide valuable insights to facilitate the establishment of an advanced vaccine monitoring system in Japan.

PLOS ONEQ3 · CROSS-FIELD

Correction: Limited indirect effects of an infant pneumococcal vaccination program in an aging population

Q3 · CROSS-FIELD

OA

Author: Perniciaro, Stephanie ; Imöhl, Matthias ; van der Linden, Mark

[This corrects the article DOI: 10.1371/journal.pone.0220453.].

100 Deals associated with 23-valent pneumococcal polysaccharide vaccine(Chengdu Institute of Biological Products)

Login to view more data